Comparing the current results to its competitors, Evolus Inc reported Revenue increase in the 1 quarter 2026 by 7.75 % year on year. The revenue growth was below Evolus Inc 's competitors' average revenue growth of 13.37 %, achieved in the same quarter.
Evolus Inc , slower than the average decrease reported by the company's competitors of -38.76 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -38.76 %
Evolus Inc 's Comment on Competition and Industry Peers
The company operates in the U.S. aesthetic neurotoxin market, competing with botulinum toxin type A products from Abbvie, Galderma S.A., Merz Pharma GmbH & CO, Revance Therapeutics, Inc., and Hugel, Inc. Medytox, Abbvie, and Galderma have submitted Biologics License Applications to the FDA for injectable botulinum toxin products, which may increase competition upon approval. In the dermal filler segment, the company's Evolysse™ collection competes with hyaluronic acid (HA)-based dermal fillers from Abbvie, Galderma, Merz, Revance, Prollenium Medical Technologies, and Obagi, as well as non-HA-based fillers from Galderma and Merz. Additional companies are developing HA gels for the U.S. market, alongside numerous international competitors. Beyond neurotoxins and dermal fillers, the company faces indirect competition from other medical aesthetics products and treatments, including laser treatments, brow lifts, chemical peels, skin care products, fat injections and removal, and cold therapy.
January 21, 2025
Evolus Reports Record Preliminary Revenue Figures for Q4 and Full-Year 2024 Amid Market Underperformance Evolus, Inc. (NASDAQ: EOLS), headquartered in Newport Beach, California, has announced its preliminary, unaudited net revenue figures for the fourth quarter and the full year ending December 31, 2024. The company, which specializes in the aesthetic beauty sector, states that its results have achieved record levels, aligning with the upper range of its previously issued guidance.The preliminary results, however, come with a caveat. They are based on the most up-to-date information available to management and are susceptible to revision until the financial audit for 2024 is finalized. This announcement has ...
July 31, 2024
Evolus Inc.: A Dynamic Future in Performance Beauty Unfolds with Upcoming Investor Day and Positive Pivotal Study Results In the ever-evolving realm of aesthetics and consumer beauty, Evolus, Inc. (NASDAQ: EOLS) emerges as a formidable player, demonstrating a sustainable commitment to innovation and strategic growth. The company recently announced significant developments that underscore its trajectory, including an upcoming Investor Day and promising results from pivotal clinical trials.Evolus is set to host an Investor Day on September 12, 2024, in the heart of New York City at the SECOND Floor venue, located at 849 6th Ave. This event serves as a critical platform for engaging with investors, stakeholder...
March 1, 2024
Evolus, Inc. (NASDAQ: EOLS), a renowned performance beauty company focused on developing an aesthetic portfolio of consumer brands, has recently revealed the results from its European head-to-head filler trial. The company plans to share these findings during its upcoming earnings conference call on March 7th and is set to launch its first-generation Cold HA Technology, branded as Evolysse in the US and Estyme in the UK and Europe, worldwide by 2025. This article aims to ly present the key facts from the aforementioned articles to shed light on Evolus achievements and future plans in the pharmaceutical industry.Key Facts:1. Evolus European Head-to-Head Filler Trial Results: - The trial results, unveiled ...
Evolus Inc., a performance beauty company, recently presented compelling data at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting, showcasing the extended duration effects of their extra-strength 40U formulation of Jeuveau. Jeuveau, the only neurotoxin dedicated exclusively to aesthetics, demonstrated impressive results lasting up to 26 weeks in Phase II clinical trials. The Phase II data for Jeuveau showed promising outcomes for individuals seeking longer-lasting effects in their aesthetic treatments. By administering the extra-strength 40U dose, Evolus Inc. was able to provide patients with a desirable extended duration of treatment results. This breakthrough in the field o...
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Merck & Co. Inc. operates primarily as a research-driven pharmaceutical company, focused on the development, manufacturing, and marketing of prescription drugs and vaccines globally. It aims to address unmet medical needs through innovative research, collaborations, and rigorous clinical trials, while promoting patient well-being and contributing to global healthcare with high-quality, affordable medications.
Nektar Therapeutics operates under a business model focused on developing and commercializing innovative medicines. The company's approach involves utilizing its proprietary technology platforms to create novel therapeutic candidates and establish partnerships with pharmaceutical and biotechnology firms for clinical development and commercialization. Nektar Therapeutics aims to bring transformative therapies to market that address significant unmet medical needs.
Ocular Therapeutix Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye. They utilize their proprietary hydrogel technology to design and manufacture sustained-release treatments that can be administered during routine eye exams and eliminate the need for patient compliance with eye drops.
Sources:
Evolus Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Evolus Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
